Literature DB >> 34599919

Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont.

Kelly R Peck1, Nathaniel Moxley-Kelly2, Gary J Badger3, Stacey C Sigmon4.   

Abstract

Posttraumatic stress disorder (PTSD) and opioid use disorder (OUD) may be associated with poor outcomes in rural areas where access to mental health services and opioid agonist treatment (OAT) is limited. This study examined the characteristics associated with a history of PTSD among a sample of individuals seeking buprenorphine treatment for OUD in Vermont, the second-most rural state in the US. Participants were 89 adults with OUD who participated in one of two ongoing randomized clinical trials examining the efficacy of an interim buprenorphine dosing protocol for reducing illicit opioid use during waitlist delays to OAT. Thirty-one percent of participants reported a history of PTSD. Those who did (PTSD+; n = 28) and did not (PTSD-; n = 61) report a history of PTSD were similar on sociodemographic and drug use characteristics. However, the PTSD+ group was less likely to have received prior OUD treatment compared to the PTSD- group (p = .02) despite being more likely to have a primary care physician (p = .009) and medical insurance (p = .002). PTSD+ individuals also reported greater mental health service utilization, more severe psychiatric, medical and drug use consequences, and greater pain severity and interference vs. PTSD- individuals (ps < 0.05). These findings indicate that a history of PTSD is prevalent and associated with worse outcomes among individuals seeking treatment for OUD in Vermont. Dissemination of screening measures and targeted interventions may help address the psychiatric and medical needs of rural individuals with OUD and a history of PTSD.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Buprenorphine; Interim treatment; Opioid use disorder; Posttraumatic stress disorder; Rurality

Mesh:

Substances:

Year:  2021        PMID: 34599919      PMCID: PMC8641000          DOI: 10.1016/j.ypmed.2021.106817

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  53 in total

1.  Interim Buprenorphine vs. Waiting List for Opioid Dependence.

Authors:  Stacey C Sigmon; Taylor A Ochalek; Andrew C Meyer; Bryce Hruska; Sarah H Heil; Gary J Badger; Gail Rose; John R Brooklyn; Robert P Schwartz; Brent A Moore; Stephen T Higgins
Journal:  N Engl J Med       Date:  2016-12-22       Impact factor: 91.245

2.  Counselors' Experiences Treating Methadone-maintained Patients with Chronic Pain: A Needs Assessment Study.

Authors:  Declan T Barry; Matthew J Bernard; Mark Beitel; Brent A Moore; Robert D Kerns; Richard S Schottenfeld
Journal:  J Addict Med       Date:  2008-06       Impact factor: 3.702

3.  Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample.

Authors:  T A Brown; L A Campbell; C L Lehman; J R Grisham; R B Mancill
Journal:  J Abnorm Psychol       Date:  2001-11

4.  Physical and mental comorbidity, disability, and suicidal behavior associated with posttraumatic stress disorder in a large community sample.

Authors:  Jitender Sareen; Brian J Cox; Murray B Stein; Tracie O Afifi; Claire Fleet; Gordon J G Asmundson
Journal:  Psychosom Med       Date:  2007-03-30       Impact factor: 4.312

5.  National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria.

Authors:  Dean G Kilpatrick; Heidi S Resnick; Melissa E Milanak; Mark W Miller; Katherine M Keyes; Matthew J Friedman
Journal:  J Trauma Stress       Date:  2013-10

6.  Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Robert H Pietrzak; Risë B Goldstein; Steven M Southwick; Bridget F Grant
Journal:  J Anxiety Disord       Date:  2010-11-26

Review 7.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

8.  Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.

Authors:  Stacey C Sigmon; Andrew C Meyer; Bryce Hruska; Taylor Ochalek; Gail Rose; Gary J Badger; John R Brooklyn; Sarah H Heil; Stephen T Higgins; Brent A Moore; Robert P Schwartz
Journal:  Addict Behav       Date:  2015-07-29       Impact factor: 3.913

9.  Time course of panic disorder and posttraumatic stress disorder onsets.

Authors:  Erin C Berenz; Timothy P York; Hanaan Bing-Canar; Ananda B Amstadter; Briana Mezuk; Charles O Gardner; Roxann Roberson-Nay
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-07-12       Impact factor: 4.328

10.  The prevalence and correlates of lifetime psychiatric disorders and trauma exposures in urban and rural settings: results from the national comorbidity survey replication (NCS-R).

Authors:  Jennifer S McCall-Hosenfeld; Sucharita Mukherjee; Erik B Lehman
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

View more
  1 in total

1.  Behavior change, health, and health disparities 2021: Rural addiction and health.

Authors:  Stephen T Higgins
Journal:  Prev Med       Date:  2021-10-07       Impact factor: 4.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.